Multiple Myeloma Research Consortium Announces Millennium: The Takeda Oncology Company as First Industry Partner in Innovative Collaboration to Advance Personalized Medicine for Multiple Myeloma
Published: Sep 29, 2011
NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Foundation (MMRF) today announced that it has entered into a multi-year collaboration with Millennium: The Takeda Oncology Company to advance the MMRF’s emerging research program in personalized medicine. Both organizations believe the MMRF’s Personalized Medicine Initiative program will enable the biological segmentation of patients and accelerate the development of new, targeted treatments and potentially curative approaches for multiple myeloma. Millennium is the first pharmaceutical company to join MMRF in advancing this new initiative.